Replies to post #80601 on Biotech Values

[DewDiligence]

ARYX:

tecarfarin…did not achieve the primary endpoint of superiority over warfarin… This was due to the virtually unprecedented performance of warfarin in this trial.

LOL—if I had a dollar for every biotech PR where failure is blamed on an unprecedented performance of the control arm, I’d probably be richer than Buffett.